Clinical Trial Update: A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating retreatment with brentuximab vedotin in classic Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma has been terminated; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Hodgkin Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-10-13